Carboplatin
Digestive System Neuroendocrine Tumor, Grade 1/2
Explore 6 assets in Digestive System Neuroendocrine Tumor, Grade 1/2 →Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00004074CT.gov Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu | — | Completed | — | — | — |
NCT00005049CT.gov Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Digestive System Neuroendocrine Tumor, Grade 1/2
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Carboplatin (this asset) | National Cancer Institute (NCI) | P2 | BB · 64 |
| Fluorouracilum | Mayo Clinic | P2/3 | BB |
| Irinotecan | National Cancer Institute (NCI) | P3 | BB |
| Oxodotreotide | Vanderbilt-Ingram Cancer Center | P4 | BB |
| L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R*,R*))- | National Cancer Institute (NCI) | P3 | BB |
| Temsirolimus | National Cancer Institute (NCI) | P2 | BB |
| Oxaliplatin | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | P2/3 | BB |
| Cyclophosphamide | Children's Oncology Group | P2 | B |
| Cis-Diamminedichloroplatinum Ii | Cambridge University Hospitals NHS Foundation Trust | P2 | B |
+35 more in the Digestive System Neuroendocrine Tumor, Grade 1/2 cohort
Other indications for Carboplatin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Lung Large Cell Carcinoma | — | P4 | A · 80 |
| Primary Peritoneal Carcinoma | — | P3 | BBB · 76 |
| Non-Small Cell Squamous Lung Carcinoma | — | P3 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- FluorouracilumMayo ClinicBB
- IrinotecanNational Cancer Institute (NCI)BB
- OxodotreotideVanderbilt-Ingram Cancer CenterBB
- L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R*,R*))-National Cancer Institute (NCI)BB
- TemsirolimusNational Cancer Institute (NCI)BB
Citation
Floatz Terminal. Carboplatin in Digestive System Neuroendocrine Tumor, Grade 1/2. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/carboplatin-digestive-system-neuroendocrine-tumor-grade-12
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →